Stockscreener 앱 받기
36.50
0.11%
0.04
전일 마감가:
$36.46
열려 있는:
$36.27
하루 거래량:
2.89M
Relative Volume:
0.79
시가총액:
$15.78B
수익:
$2.26B
순이익/손실:
$1.09B
주가수익비율:
15.58
EPS:
2.3431
순현금흐름:
$2.70B
1주 성능:
-1.38%
1개월 성능:
+0.72%
6개월 성능:
+12.79%
1년 성능:
+36.96%
1일 변동 폭
$35.85
$36.85
1주일 범위
$35.80
$37.97
52주 변동 폭
$24.05
$38.00
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
RPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
36.50 | 15.76B | 2.26B | 1.09B | 2.70B | 2.3431 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Earnings Chart Overlay Points to Royalty Pharma plc UpsideJuly 2025 Technicals & High Yield Stock Recommendations - beatles.ru
Vanguard Group Inc. Sells 676,561 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Virtu Financial LLC Increases Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Can Royalty Pharma plc expand its profit margins2025 Risk Factors & Daily Risk Controlled Trade Plans - thegnnews.com
Deutsche Bank AG Sells 1,775,038 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Charles Schwab Investment Management Inc. Has $97.20 Million Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Koss Olinger Consulting LLC Has $989,000 Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (RPRX) Q2 Receipts Up 20% - AOL.com
Henry Fernandez Steps Down from Royalty Pharma’s Board of Directors - citybiz
Royalty Pharma lead independent director Fernandez steps down By Investing.com - Investing.com Nigeria
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors - The Manila Times
Cary Street Partners Financial LLC Buys Shares of 19,580 Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Henry Fernandez steps down from Royalty Pharma board - StreetInsider
Royalty Pharma's Lead Independent Director Exits Following Successful Post-IPO Growth Period - Stock Titan
Royalty Pharma (NASDAQ:RPRX) Raised to Buy at Wall Street Zen - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Buys 55,400 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Ex-Dividend Reminder: Eli Lilly, Teleflex and Royalty Pharma - Nasdaq
Royalty Pharma PLC (NASDAQ:RPRX) Shares Sold by Forsta AP Fonden - MarketBeat
Swiss National Bank Trims Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
5 Insightful Analyst Questions From Royalty Pharma’s Q2 Earnings Call - Yahoo Finance
Is Royalty Pharma plc a potential multi baggerGlobal Markets & Fast Gaining Stock Reports - kangso.co.kr
Morgan Stanley Maintains a Buy Rating on Royalty Pharma Plc (RPRX) With a $55 PT - Insider Monkey
RPRX Q2 Deep Dive: Margins Compress Despite Solid Royalty Growth and Strategic Investments - Yahoo Finance
Royalty Pharma Director Norden Gregory Sells 33,500 Shares at $36.23 on 8/11/2025 - AInvest
CenterBook Partners LP Sells 41,728 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Royalty Pharma (NASDAQ:RPRX) - Yahoo Finance
Royalty Pharma raises 2025 portfolio receipts guidance to $3.05B-$3.15B as integrated company advances biotech funding model - MSN
Did Rising Costs and Lower Margins Just Shift Royalty Pharma's (RPRX) Investment Narrative? - simplywall.st
Royalty Pharma: Keep Delivering, Buy Confirmed (NASDAQ:RPRX) - Seeking Alpha
Royalty Pharma’s Earnings Call Highlights Strong Growth and Strategic Moves - The Globe and Mail
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's Why - MarketBeat
More Players, Better Pricing, Tough Equity Market: Royalty Deals Go Mainstream - insights.citeline.com
UBS Adjusts Price Target on Royalty Pharma to $37 From $36, Maintains Neutral Rating - MarketScreener
Royalty Pharma plc (NASDAQ:RPRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Royalty Pharma Q2 2025 Earnings: Revenue Surges to $727 Million, Exceeds Estimates - AInvest
Royalty Pharma (RPRX) Sees Revenue Rise to US$579 Million; Net Income Falls - Yahoo Finance
Royalty Pharma Reports Strong Q2 2025 Results - TipRanks
Royalty Pharma Plc Q2 Income Retreats - Nasdaq
Royalty Pharma Raises 2025 Portfolio Receipts Guidance to $3.05B-$3.15B, Achieving 20% Growth in Top Line - AInvest
Royalty Management Holding Corporation shares rise 5.65% intraday after Royalty Pharma plc reports Q2 2025 results. - AInvest
Royalty Pharma stock price target raised to $48 from $42 at BofA Securities - Investing.com UK
Royalty Pharma Q2 2025 Earnings Call Transcript - MarketBeat
Royalty Pharma (RPRX) PT Raised to $48 at BofA Securities - StreetInsider
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates - sharewise.com
Earnings call transcript: Royalty Pharma Q2 2025 shows robust growth By Investing.com - Investing.com Australia
Royalty Pharma earnings missed by $0.99, revenue fell short of estimates - Investing.com Nigeria
Royalty Pharma plc SEC 10-Q Report - TradingView
Earnings call transcript: Royalty Pharma Q2 2025 shows robust growth - Investing.com
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q2 Earnings - Yahoo Finance
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.56%
자본화:
|
볼륨(24시간):